Adageis Offers Easy-to-Use AI-Driven Solution to Help Healthcare Providers Unlock High-Value Care, Maximize Revenue

• Adageis delivers a user-friendly platform that helps providers identify high-value services while improving care quality.
• The company’s patented ProActive Care Platform leverages AI to shift providers from fee-for-service to value-based care models.
• The system integrates seamlessly with major EHR platforms to enhance operations without disrupting workflows.
• Adageis supports over 260,000 patient lives and expects that figure to more than double by the end of Q2 2025.
• The company is helping providers better understand insurance contract value and advocate for appropriate reimbursement.

For healthcare practices navigating the shift toward value-based care, the complexity of insurance contracts, quality metrics, and data reporting can be a barrier to better outcomes and stronger financial performance. Adageis, a growing healthcare technology company, is offering a unique streamlined and AI-powered software solution designed to make this transition simpler.

At the core of the company’s offering is the ProActive Care Platform, a patented, AI-centric engine that enables providers, health systems, ACOs, and CINs to identify and act on high-value opportunities within their existing operations. What sets Adageis apart is ease of use, giving practices clear, actionable insights on where value lies, and how to pursue it while maintaining or improving quality of care.

The platform has been rebranded as a fintech AI tool, focusing on helping providers navigate reimbursement structures, align with quality metrics, and increase revenue through optimized care.

Adageis’s system is designed to easily pair with existing electronic health record (“EHR”) systems. It is compatible with leading platforms like Epic, Allscripts, Cerner, AthenaHealth, and eClinicalWorks. This flexible integration approach ensures that clinics and providers can onboard without lengthy training or operational disruption.

Through a powerful application programming interface (“API”), the software analyzes patient data to surface value-based care opportunities, identify high-risk individuals, and highlight care gaps. These insights can then be used to prompt more timely interventions, coordinate more efficient care, and reduce avoidable healthcare costs.

A central feature of Adageis’s approach is its Patented Risk Engine (“PRE”), which leverages AI to improve population health management. The system continuously monitors patient data beyond the office visit and provides proactive care suggestions that can reduce emergency room visits, lower hospital admissions, and strengthen patient engagement.

As of April 2025, Adageis supports over 260,000 patient lives and has set ambitious near-term goals. By the end of Q2 2025, the company projects it will cover 580,000 lives, reach $100,000 in monthly recurring revenue, and onboard two to three new clients per month.

Another component of the platform is helping providers understand the full value of their insurance contracts. Adageis positions itself as an advocate for its clients, providing transparency and intelligence on what reimbursements practices should expect when delivering high-quality care. This kind of support can be especially beneficial for smaller organizations that may lack internal resources for revenue optimization.

Adageis is also in ongoing talks with investors to broaden its product offering, with a particular focus on tools tailored to the needs of small practices navigating the shift to value-based models.

For more information, visit the company’s website at www.Adageis.com.

NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN